Standard therapy for glioblastoma is the combination of surgical removal of the tumor, chemo- or radiation therapy. Average life expectancy after diagnosis with standard treatment of glioblastoma is 15-17 months, and the 5-year survival rate does not exceed 5-10% [1]. Today, supplementing the standard treatment protocol with innovative immunotherapeutic approaches is considered one of the most promising areas of modern neuro-oncology. In particular, dendritic cell-based therapy for brain tumors in Germany [2].
According to the clinical data, 60% of patients who received immunotherapy live longer than the average expected period, and approximately one-third of patients are completely cured. You can undergo dendritic cell therapy for glioblastoma in Germany. The Booking Health website has a comprehensive list of specialized clinics, prices for medical services, and approximate admission dates for dendritic cell vaccination.
Comparison of Glioblastoma Treatment Approaches
Glioblastoma patients and their families have to navigate complex treatment decisions – the therapeutic regimen chosen can significantly impact survival. Thus, understanding the differences between conventional and innovative therapies like DC therapy for GBM in Germany gives a chance to make informed choices.
What’s in The Conventional Protocol for Glioblastoma?
With brain tumors, traditional approaches begin with a surgical intervention [3]. Beyond all doubt, advanced imaging guidance and mapping techniques help preserve brain functions. Nevertheless, surgery faces a fundamental challenge: GBM tumor cells are surrounded by infiltrating cancer cells. This often makes complete removal impossible. Some tumor cells remain behind even with the most skilled surgical team. This potentially leads to brain tumor recurrence.
After the surgical intervention, patients typically undergo radiation therapy. It is delivered in carefully measured doses, over several weeks [4]. Radiation is suggested to effectively damage cancer cells, but it also affects healthy brain tissue. Thus, a delicate balance between treatment effectiveness and complications is a necessity. The standard protocol of 10 to 30 radiation sessions can be physically and emotionally demanding for patients. Similarly, chemotherapy, while standard practice, faces a significant obstacle in the blood-brain barrier and is connected with severe side effects.
That is why new approaches to immunotherapy, in particular the usage of dendritic cells in treatment of GBM (glioblastoma), have been actively researched in recent years. In this method, immune cells from the patient are programmed in a laboratory to recognize tumor antigens and trigger an immune response against the tumor. Such a strategy is often described as a new vaccine for glioblastoma because it actually "teaches" the immune system to find and destroy tumor cells that may remain after standard therapeutic protocol.
Enhancing The Glioblastoma Protocol With Dendritic Cell Vaccines
Dendritic cell procedures for glioblastoma in Germany emerged as a groundbreaking addition to existing methods. Overwhelming, but the discovery of dendritic cells earned Canadian scientist Ralph Steinman the Nobel Prize in Medicine in 2011 [5].
Glioblastoma vaccine therapy uses the immune cells, which act as the "officers" of the patient's immune system. This method is considered one of the modern directions of immunotherapy aimed at activating the immune system to recognize brain tumor cells.
Dendritic cells are specially processed in the laboratory to recognize and target brain tumor cells, offering several distinct advantages over conventional treatment of glioblastoma:
- Precision targeting. Traditional treatment of glioblastoma can damage healthy tissue. Dendritic cells in treatment of glioblastoma harness the patient's immune system to target cancer cells due to their specific tumor antigens – no collateral damage to healthy brain tissue.
- Adaptive response. Dendritic cell-based vaccines in brain tumors are able to form a dynamic immune response that adapts to changes in tumor antigens, which is the basis of the dendritic vaccine. Glioblastoma is characterized by high genetic variability of tumor cells, so it is this adaptive immune response that can help overcome the problem of non-response to traditional treatments.
- Long-term protection. Although traditional treatments mostly work when they are carried out, their effectiveness in long-term control is limited in an aggressive disease such as glioblastoma. Dendritic cell vaccine can form long-term immune memory, potentially helping avoid tumor recurrence.
- Minimal side effects. Vaccine for glioblastoma shows excellent tolerability – patients maintain a better quality of life during the treatment.
- Crossing the blood-brain barrier. A substantial drawback is that chemotherapy drugs are stopped by the blood-brain barrier. Activation of the immune system allows immune cells to more effectively recognize and attack brain tumor cells after administration of the glioblastoma vaccine. Germany is one of the countries where such personalized immunotherapeutic strategies are being actively implemented in treatment programs for glioblastoma patients.
The concept of this method involves a personalized approach, where therapy is created taking into account the biological characteristics of the tumor. Modern cancer centers include glioblastoma vaccine therapy in integrative treatment programs for complex brain tumors. Current research suggests that a new vaccine for glioblastoma stimulates a long-term immune response aimed at controlling the tumor process.
Practical Applications of Dendritic Cell Vaccines for GBM
Professor Frank Gansauge shares his expert perspective, drawing from over 22 years of experience in immunotherapy. This allows patients to understand better the dendritic cell vaccine for glioblastoma multiforme treatment.
His clinic has been at the forefront of developing and implementing dendritic cell vaccine for glioblastoma in Germany. Actually, he investigated peculiarities of the immune response in various types of cancer, including glioblastoma.
Clinical data and practical experience suggest a growing interest in immunotherapeutic approaches, particularly dendritic cell therapy for glioblastoma. Germany is one of the countries where these methods are used in specialized clinics as part of personalized treatment programs.
Prof. Gansauge's clinical experience in treatment with dendritic cells demonstrates its effectiveness with measurable results. His approach uses fresh, unfrozen dendritic cell vaccines. This maintains optimal cellular function and allows for targeting actual tumor antigens – distinguishing his method from clinics that freeze and store cells. Patients can see clear outcomes through MRI or CT scans. Scans may reveal shrinkage of glioblastoma cells, stabilization, or complete response to treatment.
Prof. Frank Gansauge's Revolutionary Approach: Combining Classical Treatments and Dendritic Cell Therapy For Cancer
Who Is Eligible for the Treatment of Glioblastoma with Dendritic Cells
One of the main clinical problems of modern neuro-oncology remains the treatment of an aggressive brain tumor – glioblastoma multiforme. Vaccine-based approaches are being investigated as one of the promising immunotherapeutic areas aimed at activating the immune system against tumor cells. The usage of dendritic cell vaccines in the treatment of glioblastoma is a part of a comprehensive therapeutic regimen, but not a sole and independent technique. In most cases, it is carried out:
- After the surgical tumor removal, sometimes also after the completion of the postoperative chemotherapy. This is the best treatment option: during surgery, the doctor removes malignant tissue from the brain as much as possible, and dendritic cell vaccination stimulates an anti-cancer immune response and prevents recurrence in the future. Another advantage of this option is the ability to use the removed tumor cells for manufacturing an individual cancer vaccine.
- In case of the glioblastoma recurrence after successful completion of the initial treatment. In this clinical situation, doctors may repeat the surgical treatment of glioblastoma or go straight to systemic therapies, such as chemotherapy and immunotherapy with a dendritic cell vaccine. Glioblastoma is an aggressive brain tumor, so the choice of further treatment tactics is always based on the individual characteristics of the course of the disease, previous therapy and the general condition of the patient. In the second case, tumor cells’ DNA is received through the novel method of liquid biopsy, or standard tumor antigens are used to manufacture dendritic cell vaccines (these are proteins that are present in the tumors of all patients) [9].
The course of immunization for glioblastoma does not require admission to the hospital; it is performed on an outpatient basis or in a day hospital.
During the entire course of treatment of glioblastoma, the patient remains under the supervision of a general practitioner, neurologist, and oncologist. In addition to clinical examinations, imaging diagnostics may be required – in this case, computed tomography (CT) is performed. This multidisciplinary follow-up model is about DC therapy for GBM in Germany, where treatment combines regular monitoring and a personalized approach to each patient.
In the scientific community, there is growing interest in approaches such as dendritic cell-based therapy for brain tumors. Germany continues to conduct research to more accurately assess the effectiveness and safety in different clinical cases.
Step-by-Step Dendritic Cell Procedures for Glioblastoma
Patients often feel tired of complex medical terms and the constant need to understand concepts such as oncology, immunotherapy, dendritic cell therapy, brain tumors. Germany offers patients a clearly organized treatment system where the complex path of diagnosis and therapy becomes more manageable. Dendritic cell glioblastoma treatment in Germany follows a precise protocol. It is divided into five main stages:
- Everything starts with a consultation at the clinic. You will consult with a doctor who will conduct a thorough examination and order any necessary laboratory tests. Results are a baseline for your treatment of glioblastoma monitoring.
- The second step is a minimally invasive intervention. That is, a small amount of blood is collected from your peripheral vein – about 150-200 ml. The procedure is quick and painless. Actually, you can return to your normal activities immediately after.
- Your blood cells undergo laboratory processing in a GMP-certified laboratory under strict European quality standards. The lab specialists separate blood components and isolate specific immune cells (monocytes) needed for the vaccine. Processing techniques make ot possible to obtain sufficient cellular material even from a few hundred milliliters of blood.
- The dendritic vaccine creation stage involves training dendritic cells to recognize and fight cancer cells. The specialists carry out a liquid biopsy to find components of brain cancer cells in blood, use standard glioblastoma cells’ antigens, or fragments of the removed tumor tissue. The method is chosen based on your specific case, while finding fresh components of cancer cells in the blood is typically the best option.
- The personalized vaccine administration. The vaccine is administered intradermally or subcutaneously – all on an outpatient basis.
You receive ongoing monitoring from a medical team throughout your treatment. Clinical examinations with imaging diagnostics are suggested to track your immune response. According to the results, doctors adjust the treatment plan as needed.
This approach to dynamic observation is an important part of dendritic cell procedures for glioblastoma. Germany provides all the necessary conditions to ensure that the treatment process is as comfortable and well-organized as possible for the patient, with minimal psychological and physical strain.
Results of DC Therapy for Glioblastoma
With standard treatment, the average life expectancy after diagnosing glioblastoma is 15-17 months, and the 5-year survival rate does not exceed 5-10%. Studies show that 60% of patients live longer than expected after dendritic cell vaccination, and one-third are completely cured. Given the drug's excellent tolerability, dendritic cell vaccination is indicated for most patients with glioblastoma as an additional treatment. That is why an increasing number of patients are considering dendritic cell GBM treatment in Germany as an opportunity to gain access to modern immunotherapeutic treatment programs.
The main practical results of the dendritic cell vaccine administration:
- Prevention of glioblastoma recurrence after surgical removal of the primary tumor and a course of chemotherapy. During the operation, the surgeon cannot distinguish microscopic tumor metastases from healthy tissues, so some of the malignant cells remain in the body. Chemotherapy, which is used to suppress these cells, works only during the course of treatment. Enhancing this standard regimen with GBM immunotherapy makes it possible to create a stable anti-cancer immune response that will control the development of new cancer cells for months and destroy them.
- Treatment of recurrent tumors. In many cases, people with recurrent glioblastoma are not candidates for surgical treatment. Also, recurrent tumors are often resistant to chemotherapy. In such cases, GBM immunotherapy using dendritic cells can inhibit the growth of the primary tumor and its metastases. [6]
GBM immunotherapy demonstrates excellent results; that is due to the ability of immune cells to freely move into the brain tissue and destroy cancer cells. Where surgical intervention is associated with a high risk, and chemotherapeutic drugs are unable to cross the blood-brain barrier, dendritic cell vaccination is still effective. That is why the search for dendritic cell therapy for glioblastoma abroad, in clinics specializing in personalized immunotherapy, becomes relevant for many patients.
As for the dendritic cell therapy cost, it ranges from 20,000 to 38,000 euros, depending on the combination of additional services included in the program.
From Diagnosis to Hope: Glioblastoma Patient Testimonials
The true measure of any medical treatment is the experiences of those who have undergone it. You will see a story of a patient who received a dendritic cell vaccine for glioblastoma. Germany is the country where the patient received therapy and further medical support.
The Story of Daria Rogers
In January 2024, Daria Rogers was diagnosed with GBM. Together with her husband Maurice, they actively sought alternative brain cancer treatments – eventually discovering therapy with dendritic cells in Germany. Their decision to start treatment abroad led to remarkable results just three months after therapy.
Actually, Daria's tumor was successfully removed surgically, but it was still a glioblastoma stage 4. Doctors in Ireland gave her the standard prognosis of 12-15 months to live. That is why Maurice researched international options – and found glioblastoma treatment with dendritic cells in Germany through Booking Health's medical tourism service.
The couple travelled to Germany just three weeks after Daria's surgery. That was essential: Prof. Gansauge emphasizes that earlier intervention better stimulates the immune system. It was then that Daria underwent treatment with dendritic cell therapy. Brain tumors in Germany are treated in specialist centres where such immunotherapeutic approaches are combined with standard therapies. Daria underwent the dendritic cell procedure, and what followed exceeded their expectations.
Daria tolerated her subsequent chemotherapy and radiation treatments remarkably well, maintaining energy levels throughout the demanding regimen. "I had energy to go to the clinic 5 days a week and actually tolerate the treatment without any major side effects," she recalls. Most significantly, her three-month post-treatment MRI scan showed complete clearance of cancer cells – an outcome rarely seen with standard treatments alone.
The positive results due to the work of the immune system continued. Follow-up scans, including one nearly a year after diagnosis, remained crystal clear with no evidence of cancer recurrence. Maurice notes an unexpected benefit: "I noticed a very obvious de-aging effect. Daria looked fresh and genuinely had de-aged, considering she was in the middle of chemotherapy and radiotherapy."
Daria's experience offers hope to other patients facing similar diagnoses. Her story reflects the growing interest in dendritic cell-based therapy for brain tumors abroad, especially among patients searching for innovative immunotherapy options. Her advice also emphasizes urgency: "Go early, go very quickly. Don't lose hope, don't give up. There are treatments available now that are very different from those three to five years ago."
Daria Rogers from Ireland: "Dendritic Cell Therapy Gave Me Hope"
Modern Cancer Treatment: Dendritic Cell Therapy with Booking Health
Undergoing Vaccination with Dendritic Cells for Glioblastoma in Germany
Treatment with dendritic cells in Germany – a leading destination with comprehensive support for international patients. The country's advanced medical infrastructure provides access to this innovative treatment option.
Specialized Healthcare Facilities That Offer DC Vaccination
Treating glioblastoma with dendritic cells in Germany provides benefits through immune system stimulation. This innovative treatment stimulates natural immune response by the specific training of dendritic cells that recognize and kill tumor cells. Many patients seek dendritic cell therapy for glioblastoma. Germany gives an opportunity to access such programs in the best way [10].
Leaders in brain cancer treatment with dendritic cells in Germany are LDG – Laboratories Dr. Gansauge (pioneer in this field), Praxisgemeinschaft für Zelltherapie Duderstadt GmbH & Co. KG, IOZK Immuno-Oncology Center in Cologne.
Treatment of glioblastoma with dendritic cells has not been included in the standard therapeutic protocol yet. The usage of this method is limited due to the lack of skilled healthcare professionals and the lack of equipment for manufacturing vaccines in hospitals. That is why patients consider receiving a dendritic cell vaccine for glioblastoma abroad. Doctors in Germany offer patients with glioblastoma complex treatment (surgery, chemotherapy, immunotherapy, etc.) and dendritic cell vaccination.
Going to The Foreign Hospital With Confidence
Navigating international healthcare requires careful planning and reliable support. Professional medical coordination services can significantly ease this process.
With over 12 years of experience in medical tourism, Booking Health understands the unique challenges faced by patients with glioblastoma. Their services provide support from initial clinic selection through follow-up – these allow patients to focus on their health solely. Patients often face complex organizational issues without fully realizing the essence of the complex terms that come their way – oncology, immunotherapy, dendritic cell therapy, glioblastoma. Germany offers patients a clearly organized system of medical care, where this difficult path becomes more understandable thanks to professional support.
Professional coordination services include:
- Clinic evaluation and selection based on individual medical histories
- Urgent appointments
- Visa applications, accommodation, etc.
- Interpreter services – an interpreter will be in the hospital with you
- Insurance coordination and pricing transparency
- Documentation transfer between healthcare systems
- Follow-up after the treatment completion
For families like those of Daria Rogers, dedicated support meant much. Comprehensive Booking Health approach ensures patients receive the medical care they need and the peace of mind that comes with professional guidance.
FAQ About Glioblastoma Treatment with Dendritic Cells
Send request for treatmentGlioblastoma (GB, GBM) is an aggressive brain cancer. It develops from CNS glial cells and spreads fast beyond the brain. With dendritic cell therapy, patients' own dendritic cells are modified to find and destroy glioblastoma cells. This approach is the basis of the immunotherapeutic strategy of dendritic cell vaccine glioblastoma, Germany is today one of the leading countries where this method is used in clinical practice.
DCT is a personalized treatment approach. Minimal side effects and the potential to slow tumor progression – these are the main DCT benefits. Another significant benefit highlighted is its effectiveness in cases where conventional cancer treatments are ineffective.
One important element of the results is the control after the introduction of the dendritic cell vaccine. Glioblastoma in Germany is considered a diagnosis that requires particularly careful treatment control and regular medical monitoring (MRI or CT examinations that allow doctors to assess changes in tumor size and adjust the therapeutic strategy promptly).
Yes, there are mild risks – fever, fatigue, etc. The therapy is generally safe, which is important for cancer patients. Patients are also watched for early management of adverse effects. In modern immunotherapy programs, doctors carefully monitor the body's reaction after using dendritic cells. Brain tumors in Germany are treated in specialized clinics with regular medical monitoring, which allows for timely monitoring of possible side effects.
Dendritic cell therapy is a targeted, 100% personal treatment approach in the sphere of immunotherapy (IT). What is essential, it has no side effects that are typical for chemotherapy and radiation therapy. It can be used alongside traditional cancer treatments to enhance their effectiveness. In modern neuro-oncology, patients often search for information on requests such as glioblastoma Germany. Vaccine approaches today are considered one of the promising areas of immunotherapy.
Immunotherapy treatment for GBM includes several pharmacological groups. These are dendritic cell vaccines with the patient's tumor antigens, checkpoint inhibitors given in multiple courses, and CAR T-cell therapy that modifies immune cells’ genome – the best method is chosen for a particular case.
Brain cancer immunotherapy is suggested to effectively treat recurrent tumors. Traditional cancer treatments can be rejected for some reason, but modern immune-based approaches exist that may involve the use of dendritic cells. Glioblastoma therapy strategies are increasingly discovering such methods to activate the immune system and inhibit glioblastoma cells.
You can receive dendritic cell treatment in Germany at specialized medical centers. Booking Health offers comprehensive support for international patients – treatment coordination, logistics support, follow-up care, etc. Patients consider glioblastoma dendritic cell treatment centers abroad (especially in Germany), turning to clinics with experience in conducting personalized immunotherapy programs.
The therapy demonstrates excellent tolerability – minimal side effects compared to conventional cancer treatments are observed. Most patients experience only mild reactions like fever or fatigue. These make it suitable for almost all glioblastoma patients. The security profile characteristic of glioblastoma immunotherapy with dendritic cells abroad is beneficial.
Dendritic cell therapy is a basically new immunotherapy type. Unlike medications, it uses the patient's own immune cells to fight brain cancer. Dendritic cells are processed in the laboratory to recognize and target glioblastoma tumor cells – creating a 100% personalized treatment approach. In clinical practice there is the usage of glioblastoma immunotherapy with dendritic cells. Germany is one of the countries where this approach is implemented in specialized neuro-oncology centers.
Up to 60% of patients with this therapy survive longer than usual, as clinical data suggest. Glioblastoma treatment results show that every third patient receives a complete cure with such an addition to conventional therapies. Similar results are described in the programs of glioblastoma treatment with dendritic cells abroad.
The administration protocol involves the following. Blood collection, laboratory blood cells processing, and glioblastoma vaccine injection intradermally or subcutaneously – everything is simple for a patient.
Yes. Actually, DCT is designed to enhance standard oncology treatments. It can be administered after surgical tumor removal. It can be combined with chemotherapy and radiation therapy – all to enhance treatment effectiveness and prevent GBM recurrence.
Dendritic cell GBM treatment cost in Germany can be from 20,000€ to 38,000€. There is a huge difference in cancer immunotherapy prices, which depend on the combination of services included.
Top clinics for brain cancer treatment with dendritic cells in Germany are Laboratories Dr. Gansauge (LDG), Praxisgemeinschaft für Zelltherapie Duderstadt GmbH & Co. KG, and IOZK Immuno-Oncology Center (Cologne). These glioblastoma dendritic cell treatment centers in Germany specialize in personalized immunotherapeutic approaches.
Some patients consider glioblastoma dendritic cell procedures abroad, turning to specialized clinics that have experience in conducting such immunotherapeutic programs. In Germany, these patients receive dendritic cell therapy only after a thorough assessment. Treatments are personalized and closely monitored. Also, they are integrated with standard oncology care (to support immune response and optimize disease control).
Choose dendritic cell therapy for glioblastoma abroad, and you will for sure get the best results!
Authors:
The article was edited by medical experts, board certified doctors Dr. Nadezhda Ivanisova and Dr. Daria Sukhoruchenko. For the treatment of the conditions referred to in the article, you must consult a doctor; the information in the article is not intended for self-medication!
Our editorial policy, which details our commitment to accuracy and transparency, is available here. Click this link to review our policies.
Sources:
[1] Maria Angeles Vaz-Salgado, María Villamayor, Víctor Albarrán et al. Recurrent Glioblastoma: A Review of the Treatment Options. Cancers (Basel). 2023 Aug 26;15(17):4279. doi: 10.3390/cancers15174279. [DOI] [PMC free article]
[2] Stefaan W Van Gool, Jennifer Makalowski, Linde F C Kampers et al. Dendritic cell vaccination for glioblastoma multiforme patients: has a new milestone been reached? Transl Cancer Res. 2023 Jul 28;12(8):2224–2228. doi: 10.21037/tcr-23-603. [DOI] [PMC free article]
[3] Wei Wu 1, Jessica L Klockow, Michael Zhang et al. Glioblastoma Multiforme (GBM): An overview of current therapies and mechanisms of resistance. Pharmacol Res. Author manuscript; available in PMC: 2022 Sep 1. Published in final edited form as: Pharmacol Res. 2021 Jul 21;171:105780. doi: 10.1016/j.phrs.2021.105780. [DOI] [PMC free article]
[4] Castalia Fernández, Raquel Ciérvide, Ana Díaz, Isabel Garrido, Felipe Couñago. Radiotherapy in Glioblastoma Multiforme: Evolution, Limitations, and Molecularly Guided Future. Biomedicines. 2025 Sep 1;13(9):2136. doi: 10.3390/biomedicines13092136. [DOI] [PMC free article]
[5] Roman Volchenkov, Florian Sprater, Petra Vogelsang, Silke Appel. The 2011 Nobel Prize in physiology or medicine. Scand J Immunol. 2012 Jan;75(1):1-4. doi: 10.1111/j.1365-3083.2011.02663.x. [DOI] [PubMed]
[6] Carlos Kamiya-Matsuoka, Mark R Gilbert. Treating recurrent glioblastoma: an update. CNS Oncol. 2015 Mar 13;4(2):91–104. doi: 10.2217/cns.14.55. [DOI] [PMC free article]
[7] Emilia Marta Marchelek, Afrodite Nemeth, Sidhesh Mohak et al. Dendritic Cell Therapy in Immuno-Oncology: A Potentially Key Component of Anti-Cancer Immunotherapies. Cancers 2026, 18(1), 123. doi: 10.3390/cancers18010123. [DOI]
[8] Yeganeh Mehrani, Solmaz Morovati, Fatemeh Keivan et al. Dendritic Cell-Based Cancer Vaccines: The Impact of Modulating Innate Lymphoid Cells on Anti-Tumor Efficacy. Cells 2025, 14(11), 812. doi: 10.3390/cells14110812. [DOI]
[9] Jamal A Khan, Sharmin Yaqin. Dendritic cell therapy with improved outcome in glioma multiforme―a case report. J Zhejiang Univ Sci B. 2006 Jan 19;7(2):114–117. doi: 10.1631/jzus.2006.B0114. [DOI] [PMC free article]
[10] Iwona A Ciechomska, Kamil Wojnicki, Bartosz Wojtas et al. Exploring Novel Therapeutic Opportunities for Glioblastoma Using Patient-Derived Cell Cultures. Cancers (Basel). 2023 Mar 2;15(5):1562. doi: 10.3390/cancers15051562. [DOI] [PMC free article]
Read:
Comprehensive Guide to Brain Cancer Treatment: New and Standard Treatment Options
Article menu:
- Comparison of Glioblastoma Treatment Approaches
- Who Is Eligible for the Treatment of Glioblastoma with Dendritic Cells
- Step-by-Step Dendritic Cell Procedures for Glioblastoma
- Results of DC Therapy for Glioblastoma
- From Diagnosis to Hope: Glioblastoma Patient Testimonials
- Undergoing Vaccination with Dendritic Cells for Glioblastoma in Germany
- FAQ About Glioblastoma Treatment with Dendritic Cells
Don't know where to start?
Contact Booking Health
